Pfizer-BioNTech Vaccine Effective in Patients with Myeloproliferative Neoplasms

Researchers from the UK have revealed that Pfizer-BioNTech’s COVID-19 vaccine induces effective immune responses in patients with myeloproliferative neoplasms. Myeloproliferative neoplasms (MPN) have been associated with a pro-inflammatory state and the dysregulation of natural killer cells, regulatory T cells, and effector T cell function. The researchers administered one dose of the BNT162b2 vaccine to 21 patients with a WHO-defined diagnosis of an MPN. They performed an enzyme-linked immunosorbent assay (ELISA) to test for anti-spike immunoglobulin G (IgG) antibodies at baseline and a median of 21 days following vaccination.

A positive anti-spike IgG ELISA was observed in 16 (76%) patients following vaccination and neutralizing antibodies were detected in 18 (86%) patients. Furthermore, high titers of neutralizing antibodies were observed in nine (42.9%) patients. T cell analysis was performed in 20 patients, with a response considered positive if levels of pro-inflammatory cytokines increased 3-fold from baseline. A memory T cell response was observed in 16 (80%) patients, with a CD4+ T cell response observed in 15 (75%) individuals and a CD8+ T cell response observed in seven (35%). A polyfunctional T cell response was also observed in 13 (65%) of the patients. The vaccine was safe and well-tolerated in such a population.

Ref link: https://www.medrxiv.org/content/10.1101/2021.04.27.21256096v1